SCHEMBL15033378

SCHEMBL15033378

Cn1c(CCc2cnc3c(Cl)ccc(Cl)c3n2)nc2c3ccccc3ccc21

nearest known ligand 0.45

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 15/20 0.45
TLR7 Q9NYK1 2/20 0.41
TLR8 Q9NR97 1/20 0.36
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7453581 0.86 PDE10A (0.60) PDE10ATLR7
SCHEMBL15033373 0.85 PDE10A (0.48) PDE10ATLR7TLR8
SCHEMBL15033381 0.84 PDE10A (0.45) PDE10ATLR7TLR8
SCHEMBL15033372 0.82 PDE10A (0.67) PDE10ATLR7
SCHEMBL15033380 0.82 PDE10A (0.44) PDE10ATLR7TLR8
SCHEMBL19846387 0.80 PDE10A (0.56) PDE10ATLR7TLR8
SCHEMBL10309461 0.77 PDE10A (0.45) PDE10ATLR7TLR8
SCHEMBL15033393 0.77 PDE10A (0.67) PDE10ATLR7
SCHEMBL10309402 0.76 PDE10A (0.61) PDE10ATLR7TLR8
SCHEMBL12068168 0.76 PDE10A (0.69) PDE10ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 US disclosed
US-9834564-B2 Substituted quinolines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2017-12-05 US disclosed
US-20150166571-A1 Heteroaryl Compounds and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. 2015-06-18 US disclosed
US-8969349-B2 Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2015-03-03 US disclosed
US-20130158003-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS PDE10A, PDE2A, PDE3A PDE10A 1/4885TLR7 1695/4885TLR8 2698/4885
US-20130158003-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN PDE10A 2086/4885TLR7 4107/4885TLR8 3746/4885
US-20150166571-A1 Heteroaryl Compounds and Methods of Use Thereof COMT, GPR119, NLN PDE10A 2086/4885TLR7 4107/4885TLR8 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.